HowardKaufmanMD
General Surgery • Boston, MASurgical Oncology (Other than Breast)
Professor of Surgery, Loyola University-Stritch School of Medicine
Dr. Kaufman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-726-6607
Education & Training
Boston University Medical CenterResidency, Surgery, 1990 - 1995
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1988 - 1990
Ascension Illinois/Saint FrancisResidency, Internal Medicine, 1988 - 1988
University of Illinois College of Medicine at ChicagoInternship, Transitional Year, 1986 - 1987
Loyola University Chicago Stritch School of MedicineClass of 1986
Certifications & Licensure
VA State Medical License 1900 - Present
MA State Medical License 1990 - 2025
ME State Medical License 2020 - 2021
NJ State Medical License 2014 - 2017
IL State Medical License 1986 - 2014
NY State Medical License 1997 - 2011
MD State Medical License 1989 - 1998- American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) Start of enrollment: 2015 Dec 17
Publications & Presentations
PubMed
- 1286 citationsManaging toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Wor...Igor Puzanov, Adi Diab, K. Abdallah, Clifton O. Bingham, C. Brogdon
Journal for Immunotherapy of Cancer. 2017-11-21 - 421 citationsRandomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients...Jason Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem
Journal of Clinical Oncology. 2017-10-05 - 442 citationsOncolytic viruses: a new class of immunotherapy drugs.Howard L Kaufman, Frederick J Kohlhapp, Andrew Zloza
Nature Reviews. Drug Discovery. 2015-09-01
Journal Articles
- Author Correction: Integrating Oncolytic Viruses in Combination Cancer ImmunotherapyHoward Kaufman, MD, Nature
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
